| Trial ID: | L0576 |
| Source ID: | NCT00213291
|
| Associated Drug: |
Darbepoetin Alfa
|
| Title: |
Darbepoetin Treatment of Anemia in Children With Chronic Renal Failure
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Kidney Failure, Chronic
|
| Interventions: |
DRUG: darbepoetin alfa
|
| Outcome Measures: |
Primary: The safety of darbepoetin when administered at an increased dosing interval, 40 weeks | Secondary: Safety and tolerability of darbepoetin, 40 weeks|Proportion of subjects who receive red blood cell transfusions, 40 weeks|Percentage of Hb data points that exceed upper target of 125 g/L, 16-36 weeks|Incidence of anti-erythropoietin antibody formation, 40 weeks
|
| Sponsor/Collaborators: |
Sponsor: The Hospital for Sick Children
|
| Gender: |
ALL
|
| Age: |
CHILD
|
| Phases: |
PHASE3
|
| Enrollment: |
40
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2005-04
|
| Completion Date: |
2005-10
|
| Results First Posted: |
|
| Last Update Posted: |
2013-08-26
|
| Locations: |
The Hospital for Sick Children, Toronto, Ontario, M5G 1X8, Canada
|
| URL: |
https://clinicaltrials.gov/show/NCT00213291
|
